| M | T | W | T | F | S | S | |
|---|---|---|---|---|---|---|---|
 | 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
BIONOMICS LIMITED (BNO)
Stock Code: BNO
Listing Date: 1999-12-21 00:00:00
Website: http://www.bionomics.com.au/
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities:
Developer of innovative treatments for cancer, mutiple sclerosis, anxiety and epilepsy.
Address:
31 Dalgleish Street
THEBARTON
SA 5031
Phone: 08 8354 6100
Fax: 08 8354 6199
Executives & Directors
Dr Peter Jonson, Chairman, Non Exec. Director
Dr Deborah Rathjen, Managing Director, CEO
Mr Trevor Tappenden, Non Exec. Director
Dr Errol De Souza, Non Exec. Director
Mr Stephen Birrell, CFO
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Click here to view this company's details on the ASX site
Company Events
BIONOMICS LIMITED (BNO)
| Appendix 3B | Wed, 19 Nov 2008 |
| Change of Director`s Interest Notice | Wed, 19 Nov 2008 |
| Open Briefing - BNO CEO on Recent Developments | Wed, 12 Nov 2008 |
| Austin Health Comes On Board BNC105 Trial | Wed, 5 Nov 2008 |
| AGM 2008 CEO Address | Wed, 5 Nov 2008 |
| Chairman`s Address to Shareholders | Wed, 5 Nov 2008 |
| BNO 2008 AGM Results | Wed, 5 Nov 2008 |
| BNO - Appendix 4C | Fri, 31 Oct 2008 |
| Notice of Annual General Meeting/Proxy Form | Fri, 3 Oct 2008 |
| BNO Annual Report 2007/2008 | Tue, 30 Sep 2008 |
| BNC105 Clinical Trial Update | Tue, 16 Sep 2008 |
| US and European Investor Presentation | Mon, 8 Sep 2008 |
| Bionomics NOW September Newsletter | Fri, 5 Sep 2008 |
| BNC210 Decreases Anxiety in Animal Models | Mon, 1 Sep 2008 |
| Appendix 3B | Fri, 29 Aug 2008 |
| BNO 07/08 Preliminary Final Results | Fri, 22 Aug 2008 |
| BNO Extends Contract of CEO | Fri, 8 Aug 2008 |
| Appendix 4C - quarterly | Thu, 31 Jul 2008 |
| BNO Audio Broadcast | Thu, 17 Jul 2008 |
| Appendix 3B | Wed, 16 Jul 2008 |
| BNO Completes GMP Synthesis of BNC210 | Wed, 9 Jul 2008 |
| BNO Newsletter - July 2008 | Mon, 30 Jun 2008 |
| Open Briefing - BNO. Merck Serono Development Agreement | Tue, 24 Jun 2008 |
| Change in substantial holding | Tue, 24 Jun 2008 |
| Merck Serono and BNO announce MS Agreement | Thu, 19 Jun 2008 |
| Trading Halt | Wed, 18 Jun 2008 |
| BNC105 - Top 5 Most Promising Drugs Entering Phase 1 Trials | Tue, 3 Jun 2008 |
| Appendix 4C - quarterly | Tue, 29 Apr 2008 |
| BNO - BNC210 Manufacture Contract Awarded | Wed, 16 Apr 2008 |
| BNO Presents at AACR | Mon, 14 Apr 2008 |
| Appendix 3B | Mon, 7 Apr 2008 |
| BNO April Newsletter | Wed, 2 Apr 2008 |
| Appendix 3B | Tue, 1 Apr 2008 |
| BNO - Final Director`s Interest Notice | Tue, 1 Apr 2008 |
| BNO 708A announcement | Fri, 14 Mar 2008 |
| BNO Appendix 3Y | Fri, 14 Mar 2008 |
| Change in substantial holding | Fri, 14 Mar 2008 |
| Appendix 3B | Tue, 11 Mar 2008 |
| Bionomics Advances Anti-Anxiety Candidate BNC210 | Tue, 11 Mar 2008 |
| Initial Director`s Interest Notice | Wed, 5 Mar 2008 |
| Bionomics Strengthens Board with New Appointment | Thu, 28 Feb 2008 |
| Open Briefing - BNO. Phase I Clinical Trials of BNC105 | Wed, 27 Feb 2008 |
| Treatment of First Patient in Ph I clinical trial of BNC105 | Tue, 26 Feb 2008 |
| BNO Audio Broadcast | Thu, 21 Feb 2008 |
| Appendix 4D | Wed, 20 Feb 2008 |
| GENMAB MILESTONE PAYMENT | Tue, 19 Feb 2008 |
| Appendix 4C - quarterly | Thu, 31 Jan 2008 |
| Appendix 3B | Mon, 17 Dec 2007 |
| Change of Director`s Interest Notice | Mon, 3 Dec 2007 |
| Change of Director`s Interest Notice | Mon, 3 Dec 2007 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.